Efficacy of nonprescription doses of ibuprofen for treating migraine headache. a randomized controlled trial
- PMID: 11554954
- DOI: 10.1046/j.1526-4610.2001.041007665.x
Efficacy of nonprescription doses of ibuprofen for treating migraine headache. a randomized controlled trial
Abstract
Objective: To evaluate the efficacy and safety of ibuprofen, 200 mg and 400 mg, compared with placebo and each other for the treatment of pain of migraine headache.
Background: Migraine headache is a common illness with significant social and economic impact.
Design: Randomized, placebo-controlled, double-blind trial of 6 hours' treatment duration.
Methods: Fifteen investigators at 17 private practice and referral centers in the United States participated in this study of 660 outpatient adults aged 18 to 84 years with migraine headache of moderate to severe intensity. Each patient was randomly assigned to a single dose of study medication: ibuprofen 200 mg (n = 216) or 400 mg (n = 223), or placebo (n = 221). The percentage of patients with a reduction in baseline headache intensity from severe or moderate to mild or none 2 hours after treatment and the headache pain intensity difference from baseline at 2 hours were the primary efficacy measures. Secondary outcomes included other measures of pain relief, severity differences from baseline for migraine-associated symptoms of nausea, photophobia, phonophobia, and functional disability, and percentage of patients with migraine-associated symptoms reduced to none.
Results: Significantly (P < or = .006) more patients treated with ibuprofen, 200 mg or 400 mg, reported mild to no pain after 2 hours (41.7% and 40.8%, respectively), compared with those treated with placebo (28.1%). The mean pain intensity difference from baseline measured at 2 hours was significantly (P < or = .001) greater for patients treated with ibuprofen 200 mg or 400 mg (0.68 and 0.65, respectively), compared with those treated with placebo (0.39). Statistically significant differences in favor of both doses of ibuprofen over placebo were observed for mean pain intensity difference at 1 hour after treatment. In patients with severe baseline pain intensity, ibuprofen, 400 mg, was significantly (P < or = .048) superior to placebo for the primary efficacy end points, while ibuprofen, 200 mg, was not. Ibuprofen, 200 mg and 400 mg, were statistically significantly more effective than placebo for all clinically important secondary pain relief outcomes. Mean severity changes of migraine-associated symptoms of nausea, photophobia, phonophobia, and functional disability at 2 and 6 hours were significantly (P < or = .03) in favor of both doses of ibuprofen over placebo, and results for the percentage of patients with symptoms reduced to none consistently, although less often statistically significant, favored ibuprofen. No statistically significant differences in adverse events were found among treatment groups.
Conclusions: Ibuprofen at doses of 200 mg and 400 mg is an efficacious, cost-effective, well-tolerated, single-ingredient nonprescription treatment for pain of migraine headache. In addition, while not always statistically significant, ibuprofen provided a beneficial effect on associated symptoms of migraine including nausea, photophobia, phonophobia, and functional disability.
Similar articles
-
Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis.Ann Pharmacother. 2007 Nov;41(11):1782-91. doi: 10.1345/aph.1K121. Epub 2007 Sep 18. Ann Pharmacother. 2007. PMID: 17878396 Review.
-
Treatment of menstruation-associated migraine with the nonprescription combination of acetaminophen, aspirin, and caffeine: results from three randomized, placebo-controlled studies.Clin Ther. 1999 Mar;21(3):475-91. doi: 10.1016/S0149-2918(00)88303-4. Clin Ther. 1999. PMID: 10321417 Clinical Trial.
-
Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials.Arch Neurol. 1998 Feb;55(2):210-7. doi: 10.1001/archneur.55.2.210. Arch Neurol. 1998. PMID: 9482363 Clinical Trial.
-
Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.CNS Drugs. 2003;17(9):653-67. doi: 10.2165/00023210-200317090-00005. CNS Drugs. 2003. PMID: 12828501 Clinical Trial.
-
Ibuprofen with or without an antiemetic for acute migraine headaches in adults.Cochrane Database Syst Rev. 2010 Oct 6;(10):CD008039. doi: 10.1002/14651858.CD008039.pub2. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008039. doi: 10.1002/14651858.CD008039.pub3. PMID: 20927770 Free PMC article. Updated. Review.
Cited by
-
Headaches in adults in supplementary health: management.Rev Assoc Med Bras (1992). 2024 Mar 15;70(1):e023D701. doi: 10.1590/1806-9282.023D701. eCollection 2024. Rev Assoc Med Bras (1992). 2024. PMID: 38511747 Free PMC article. No abstract available.
-
Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab.Pharmaceuticals (Basel). 2021 Sep 13;14(9):924. doi: 10.3390/ph14090924. Pharmaceuticals (Basel). 2021. PMID: 34577624 Free PMC article.
-
Out-of-hospital assessment and treatment of adults with atraumatic headache.J Am Coll Emerg Physicians Open. 2020 Jan 21;1(1):17-23. doi: 10.1002/emp2.12006. eCollection 2020 Feb. J Am Coll Emerg Physicians Open. 2020. PMID: 33000009 Free PMC article.
-
Response to: Costs and savings associated with a pharmacists prescribing for minor ailments program in Saskatchewan.Cost Eff Resour Alloc. 2018 Nov 22;16:62. doi: 10.1186/s12962-018-0159-y. eCollection 2018. Cost Eff Resour Alloc. 2018. PMID: 30479578 Free PMC article. No abstract available.
-
Caffeine in the management of patients with headache.J Headache Pain. 2017 Oct 24;18(1):107. doi: 10.1186/s10194-017-0806-2. J Headache Pain. 2017. PMID: 29067618 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical